NCT00139152

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Creighton University · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.

Detailed description

Traditional methods of sampling secretions from the lower respiratory tract include sputum collection, sputum induction, and bronchoscopy with bronchoalveolar lavage. They cannot be repeated within a short period of time because of their invasiveness, and because the procedures themselves may include an inflammatory response. The need to monitor inflammation in the lungs has led to the exploration of exhaled gases and condensates. Noninvasive monitoring may assist in differential diagnosis of pulmonary diseases, assessment of disease severity and response to treatment.

Conditions

• Lung Disease

Interventions

Type	Name	Description
DRUG	Placebo	Saline, Sub-Cuteanous (SQ)
DRUG	Xolair	Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ

Timeline

• Start date: 2005-09-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2005-08-31
• Last updated: 2014-01-07

Locations

2 sites across 1 country: United States